Overview

  • Product nameAnti-CD45 antibody [IBL-3/16]
    See all CD45 primary antibodies
  • Description
    Rat monoclonal [IBL-3/16] to CD45
  • SpecificityThis antibody recognises mouse CD45. Enhances the MHC Class II induced cluster formation of mouse B cells.
  • Tested applicationsSuitable for: IP, ICC/IF, Flow Cyt, IHC-Frmore details
    Unsuitable for: IHC-P,IHC-R or WB
  • Species reactivity
    Reacts with: Mouse
    Does not react with: Rat, Human
  • Immunogen

    Purified B cells from mouse lymph nodes.

Applications

Our Abpromise guarantee covers the use of ab23910 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration.
Flow Cyt 1/1000. Use 50µl of the suggested working dilution to label 105 cells in 100µl.



ab18407-Rat monoclonal IgG1, is suitable for use as an isotype control with this antibody.
IHC-Fr 1/500.
  • Application notesIs unsuitable for IHC-P,IHC-R or WB.
  • Target

    • FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
    • Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
      Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
    • Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
      Contains 2 fibronectin type-III domains.
      Contains 2 tyrosine-protein phosphatase domains.
    • DomainThe first PTPase domain interacts with SKAP1.
    • Post-translational
      modifications
      Heavily N- and O-glycosylated.
    • Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
    • Information by UniProt
    • Database links
    • Alternative names
      • B220 antibody
      • CD 45 antibody
      • CD45 antibody
      • CD45 antigen antibody
      • CD45R antibody
      • GP180 antibody
      • L-CA antibody
      • LCA antibody
      • Leukocyte common antigen antibody
      • loc antibody
      • Ly-5 antibody
      • LY5 antibody
      • Ly5, homolog of antibody
      • Lyt-4 antibody
      • OTTHUMP00000033813 antibody
      • OTTHUMP00000033816 antibody
      • OTTHUMP00000033817 antibody
      • OTTHUMP00000038574 antibody
      • Protein tyrosine phosphatase receptor type c polypeptide antibody
      • protein tyrosine phosphatase, receptor type, C antibody
      • Ptprc antibody
      • PTPRC_HUMAN antibody
      • Receptor-type tyrosine-protein phosphatase C antibody
      • T200 antibody
      • T200 glycoprotein antibody
      • T200 leukocyte common antigen antibody
      see all

    Anti-CD45 antibody [IBL-3/16] images

    • ab23910 staining the CD45 in Mouse brain tissue sections by IHC-Fr (frozen sections). Tissue was fixed with acetone and blocked with 5% BSA for 10 hours at 20°C. Samples were incubated with primary antibody (1/100) for 1 hour at 20°C. An Alexa Fluor®-conjugated goat anti-rat IgG polyclonal (1/300) was used as the secondary antibody.

      See Abreview

    References for Anti-CD45 antibody [IBL-3/16] (ab23910)

    This product has been referenced in:
    • Lee BC  et al. Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation by suppressing K63-linked ubiquitination of MyD88. Proc Natl Acad Sci U S A 113:E165-71 (2016). Mouse . Read more (PubMed: 26719415) »

    See 1 Publication for this product

    Product Wall

    We recommend that alignment should be over 85% to predict that an antibody will detect in a different species. The alignment between the mouse protein and the human immunogen is below the threshold at 80%. I would therefore suggest this antibody would ...

    Read More
    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Immunohistochemistry (Frozen sections)
    Sample Mouse Tissue sections (brain)
    Specification brain
    Fixative Acetone
    Permeabilization No
    Blocking step BSA as blocking agent for 10 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
    Username

    Abcam user community

    Verified customer

    Submitted Apr 15 2010

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"